Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Change in Cash (2019 - 2025)

C4 Therapeutics' Change in Cash history spans 7 years, with the latest figure at $15.8 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 480.58% year-over-year to $15.8 million; the TTM value through Dec 2025 reached $19.1 million, up 126.87%, while the annual FY2025 figure was $19.1 million, 126.87% up from the prior year.
  • Change in Cash reached $15.8 million in Q4 2025 per CCCC's latest filing, up from -$19.3 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $184.9 million in Q2 2021 to a low of -$118.4 million in Q3 2021.
  • Average Change in Cash over 5 years is -$5.3 million, with a median of -$6.2 million recorded in 2022.
  • Peak YoY movement for Change in Cash: plummeted 420.04% in 2021, then surged 480.58% in 2025.
  • A 5-year view of Change in Cash shows it stood at -$84.6 million in 2021, then soared by 76.6% to -$19.8 million in 2022, then surged by 431.4% to $65.6 million in 2023, then crashed by 106.33% to -$4.1 million in 2024, then soared by 480.58% to $15.8 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Change in Cash are $15.8 million (Q4 2025), -$19.3 million (Q3 2025), and $26.9 million (Q2 2025).